CATXPerspective Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$110M
- 25% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$47M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired625% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $10M | $0 | $1M | — | — | |
| Operating income | −$3M | −$9M | −$41M | −$91M | −$114M | 25% |
| Net income | −$3M | −$11M | −$47M | −$79M | −$103M | 30% |
| Operating cash flow | −$3M | −$10M | −$37M | −$18M | −$82M | 351% |
| Capex | $381K | $282K | $1M | $54M | $13M | 77% |
| Stock-based comp | $386K | $983K | $4M | $5M | $9M | 66% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $1M · 5
- Net
- −$1M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 110 | — |
| FY2024 | — | — | 128 | — |
| FY2023 | — | — | 160 | — |